Research ArticleArticle
Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2)
Brian D.M. Tom, Vinod Chandran, Vernon T. Farewell, Cheryl F. Rosen and Dafna D. Gladman
The Journal of Rheumatology April 2015, jrheum.140857; DOI: https://doi.org/10.3899/jrheum.140857
Brian D.M. Tom
From the MRC Biostatistics Unit, UK Institute of Public Health, Cambridge, UK; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, the Canadian Institutes of Health Research, and the Krembil Foundation. Prof. V.T. Farewell and B.D. Tom were supported by the UK Medical Research Council (Unit Programme numbers U105261167 and MC_UP_1302/3). B.D. Tom, PhD, MRC Biostatistics Unit, UK Institute of Public Health; V. Chandran, MBBS, MD, DM, PhD, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V.T. Farewell, PhD, MRC Biostatistics Unit, UK Institute of Public Health; C.F. Rosen, MD, FRCPC, Division of Dermatology, Toronto Western Hospital, University of Toronto; D.D. Gladman, MD, FRCPC, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, 1E-410B, Toronto Western Hospital, 399 Bathurst St., Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication January 16, 2015.
Vinod Chandran
From the MRC Biostatistics Unit, UK Institute of Public Health, Cambridge, UK; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, the Canadian Institutes of Health Research, and the Krembil Foundation. Prof. V.T. Farewell and B.D. Tom were supported by the UK Medical Research Council (Unit Programme numbers U105261167 and MC_UP_1302/3). B.D. Tom, PhD, MRC Biostatistics Unit, UK Institute of Public Health; V. Chandran, MBBS, MD, DM, PhD, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V.T. Farewell, PhD, MRC Biostatistics Unit, UK Institute of Public Health; C.F. Rosen, MD, FRCPC, Division of Dermatology, Toronto Western Hospital, University of Toronto; D.D. Gladman, MD, FRCPC, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, 1E-410B, Toronto Western Hospital, 399 Bathurst St., Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication January 16, 2015.
Vernon T. Farewell
From the MRC Biostatistics Unit, UK Institute of Public Health, Cambridge, UK; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, the Canadian Institutes of Health Research, and the Krembil Foundation. Prof. V.T. Farewell and B.D. Tom were supported by the UK Medical Research Council (Unit Programme numbers U105261167 and MC_UP_1302/3). B.D. Tom, PhD, MRC Biostatistics Unit, UK Institute of Public Health; V. Chandran, MBBS, MD, DM, PhD, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V.T. Farewell, PhD, MRC Biostatistics Unit, UK Institute of Public Health; C.F. Rosen, MD, FRCPC, Division of Dermatology, Toronto Western Hospital, University of Toronto; D.D. Gladman, MD, FRCPC, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, 1E-410B, Toronto Western Hospital, 399 Bathurst St., Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication January 16, 2015.
Cheryl F. Rosen
From the MRC Biostatistics Unit, UK Institute of Public Health, Cambridge, UK; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, the Canadian Institutes of Health Research, and the Krembil Foundation. Prof. V.T. Farewell and B.D. Tom were supported by the UK Medical Research Council (Unit Programme numbers U105261167 and MC_UP_1302/3). B.D. Tom, PhD, MRC Biostatistics Unit, UK Institute of Public Health; V. Chandran, MBBS, MD, DM, PhD, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V.T. Farewell, PhD, MRC Biostatistics Unit, UK Institute of Public Health; C.F. Rosen, MD, FRCPC, Division of Dermatology, Toronto Western Hospital, University of Toronto; D.D. Gladman, MD, FRCPC, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, 1E-410B, Toronto Western Hospital, 399 Bathurst St., Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication January 16, 2015.
Dafna D. Gladman
From the MRC Biostatistics Unit, UK Institute of Public Health, Cambridge, UK; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, the Canadian Institutes of Health Research, and the Krembil Foundation. Prof. V.T. Farewell and B.D. Tom were supported by the UK Medical Research Council (Unit Programme numbers U105261167 and MC_UP_1302/3). B.D. Tom, PhD, MRC Biostatistics Unit, UK Institute of Public Health; V. Chandran, MBBS, MD, DM, PhD, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V.T. Farewell, PhD, MRC Biostatistics Unit, UK Institute of Public Health; C.F. Rosen, MD, FRCPC, Division of Dermatology, Toronto Western Hospital, University of Toronto; D.D. Gladman, MD, FRCPC, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, 1E-410B, Toronto Western Hospital, 399 Bathurst St., Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication January 16, 2015.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2)
Brian D.M. Tom, Vinod Chandran, Vernon T. Farewell, Cheryl F. Rosen, Dafna D. Gladman
The Journal of Rheumatology Apr 2015, jrheum.140857; DOI: 10.3899/jrheum.140857